130 related articles for article (PubMed ID: 33408297)
1. Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets.
Ajima H; Kai Y; Fujimaki J; Akashi S; Morita A; Ezaki O; Kamei Y; Miura S
J Toxicol Sci; 2021; 46(1):11-24. PubMed ID: 33408297
[TBL] [Abstract][Full Text] [Related]
2. Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue.
Wang L; Zheng ZG; Meng L; Zhu L; Li P; Chen J; Yang H
Cell Biol Toxicol; 2021 Jun; 37(3):441-460. PubMed ID: 33034787
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting.
Oyabu M; Takigawa K; Mizutani S; Hatazawa Y; Fujita M; Ohira Y; Sugimoto T; Suzuki O; Tsuchiya K; Suganami T; Ogawa Y; Ishihara K; Miura S; Kamei Y
FASEB J; 2022 Feb; 36(2):e22152. PubMed ID: 35061305
[TBL] [Abstract][Full Text] [Related]
4. FOXO1 suppresses PGC-1β gene expression in skeletal muscles.
Nakai S; Oyabu M; Hatazawa Y; Akashi S; Kitamura T; Miura S; Kamei Y
FEBS Open Bio; 2020 Jul; 10(7):1373-1388. PubMed ID: 32433820
[TBL] [Abstract][Full Text] [Related]
5. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.
Hanai J; Cao P; Tanksale P; Imamura S; Koshimizu E; Zhao J; Kishi S; Yamashita M; Phillips PS; Sukhatme VP; Lecker SH
J Clin Invest; 2007 Dec; 117(12):3940-51. PubMed ID: 17992259
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK/FOXO1 signaling.
Du H; Ma Y; Wang X; Zhang Y; Zhu L; Shi S; Pan S; Liu Z
Am J Physiol Endocrinol Metab; 2023 Mar; 324(3):E279-E287. PubMed ID: 36724125
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D Attenuates FOXO1-Target Atrophy Gene Expression in C2C12 Muscle Cells.
Hirose Y; Onishi T; Miura S; Hatazawa Y; Kamei Y
J Nutr Sci Vitaminol (Tokyo); 2018; 64(3):229-232. PubMed ID: 29962435
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
9. FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy.
O'Neill BT; Bhardwaj G; Penniman CM; Krumpoch MT; Suarez Beltran PA; Klaus K; Poro K; Li M; Pan H; Dreyfuss JM; Nair KS; Kahn CR
Diabetes; 2019 Mar; 68(3):556-570. PubMed ID: 30523026
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control.
Kamei Y; Miura S; Suzuki M; Kai Y; Mizukami J; Taniguchi T; Mochida K; Hata T; Matsuda J; Aburatani H; Nishino I; Ezaki O
J Biol Chem; 2004 Sep; 279(39):41114-23. PubMed ID: 15272020
[TBL] [Abstract][Full Text] [Related]
12. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
13. A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy.
Kang J; Jeong MG; Oh S; Jang EJ; Kim HK; Hwang ES
FEBS Lett; 2014 Jan; 588(1):79-85. PubMed ID: 24269680
[TBL] [Abstract][Full Text] [Related]
14. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
Forcadell-Peris MJ; de Diego-Cabanes C
Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
[TBL] [Abstract][Full Text] [Related]
15. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
16. Asparagine reduces the mRNA expression of muscle atrophy markers via regulating protein kinase B (Akt), AMP-activated protein kinase α, toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling in weaning piglets after lipopolysaccharide challenge.
Wang X; Liu Y; Wang S; Pi D; Leng W; Zhu H; Zhang J; Shi H; Li S; Lin X; Odle J
Br J Nutr; 2016 Oct; 116(7):1188-1198. PubMed ID: 27572423
[TBL] [Abstract][Full Text] [Related]
17. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice.
Silveira WA; Gonçalves DA; Machado J; Lautherbach N; Lustrino D; Paula-Gomes S; Pereira MG; Miyabara EH; Sandri M; Kettelhut IC; Navegantes LC
FASEB J; 2020 Sep; 34(9):12946-12962. PubMed ID: 32772437
[TBL] [Abstract][Full Text] [Related]
18. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect.
Cao P; Hanai J; Tanksale P; Imamura S; Sukhatme VP; Lecker SH
FASEB J; 2009 Sep; 23(9):2844-54. PubMed ID: 19406843
[TBL] [Abstract][Full Text] [Related]
19. FOXO1 delays skeletal muscle regeneration and suppresses myoblast proliferation.
Yamashita A; Hatazawa Y; Hirose Y; Ono Y; Kamei Y
Biosci Biotechnol Biochem; 2016 Aug; 80(8):1531-5. PubMed ID: 27010781
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate.
Watanabe K; Oda S; Matsubara A; Akai S; Yokoi T
Toxicol Lett; 2019 Jun; 307():49-58. PubMed ID: 30853469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
